Drug
Ticagrelor Monotherapy
Ticagrelor Monotherapy: highest development phase Post-Market, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ticagrelor monotherapy NCT04484259 | Post-Market | Diabetes Mellitus, Type 2 |
Latest
No recent events.
Follow Ticagrelor Monotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.